T-Bird Pharma Inc, a Canadian pharmaceutical company, is considered the first in British Columbia to become a publicly traded medical marijuana firm. The company’s primary subsidiary, Thunderbird Biomedical Inc, is also one of the first in Canada to get a production license under the country’s Marihuana for Medical Purposes Regulations (MMPR).
Producing premium high-grade medicinal marijuana, T-Bird Pharma currently has a portfolio of more than 60 cannabis strains. This includes some well-known strains such as Island Honey, Blue Gold, and Pink Kush.
T-Bird’s alpha cannabis facility is operated by Thunderbird Biomedical and is situated in Saanich, Victoria. The facility covers 3,178 square feet, which may produce and sell – as per its Health Canada license – a maximum of 243 kg of dried marijuana. Thunderbird Biomedical is the fifth Canadian company to obtain this license.
A second facility of T-Bird Pharma is also located in Victoria, British Columbia. Of this 43,500-square foot facility, some 28,966 square feet will be for floor space and there is also an option for a mezzanine space of 14,500 square feet. Thunderbird has started infrastructure preparations in this facility, aiming to have Health Canada inspect it by the first quarter of 2015.
T-Bird Pharma Inc was founded in 2007 under the name Firebird Capital Partners. It also operated as Firebird Energy, Inc, exploring properties of natural gas and oil in Western Canada. After a recent reverse takeover, the company became T-Bird Pharma Inc in August 2014.
T-Bird Pharma is now traded as TPI in the TSX Venture Exchange, having a market cap of CAD 6.95 M.
Key executives at T-Bird Pharma include Founder and CEO Robert Gagnon, VP of Operations Rick Morris, VP of Quality Assurance Karen Parent, and CFO Chris Taylor.
T-Bird Pharma Inc.
4420 West Saanich Rd
PO Box 24076
Royal Oak, Victoria, BC V8Z 7E7